In this section
@article{Openshaw:2015:10.2217/whe.15.6,
author = {Openshaw, MR and Fotopoulou, C and Blagden, S and Gabra, H},
doi = {10.2217/whe.15.6},
journal = {Women's Health},
pages = {355--367},
title = {The next steps in improving the outcomes of advanced ovarian cancer},
url = {http://dx.doi.org/10.2217/whe.15.6},
volume = {11},
year = {2015}
}
TY - JOUR
AB - Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication. Second, acquisition of chemotherapy resistance results in untreatable progressive disease. Advances in treatment of advanced ovarian cancer involve a spectrum of interventions including improvements in frontline debulking surgery and combination chemotherapy. Anti-angiogenic factors have been shown to have activity in frontline and recurrent disease while novel chemotherapeutic agents and targeted treatments are in development particularly for disease that is resistant to platinum-based chemotherapy. These developments aim to improve the progression-free and overall survival of women with advanced ovarian cancer.
AU - Openshaw,MR
AU - Fotopoulou,C
AU - Blagden,S
AU - Gabra,H
DO - 10.2217/whe.15.6
EP - 367
PY - 2015///
SN - 1745-5057
SP - 355
TI - The next steps in improving the outcomes of advanced ovarian cancer
T2 - Women's Health
UR - http://dx.doi.org/10.2217/whe.15.6
UR - http://www.ncbi.nlm.nih.gov/pubmed/26102473
UR - http://hdl.handle.net/10044/1/43615
VL - 11
ER -
Learn more about the work of Ovarian Cancer Action